Navigation Links
Vantage Health South African Subsidiary Negotiates Supply Agreement With Major South African Retail Group
Date:8/2/2011

CAPE TOWN, South Africa, Aug. 02, 2011 /PRNewswire/ -- Vantage Health (OTC:BB – ticker symbol VNTH), ("Vantage"), announced today that its 51% owned South African subsidiary, Moxisign (PTY) Ltd., ("Moxisign"), is finalizing a pricing structure for a Supply Agreement with the generic pharmaceutical division of a major Johannesburg Stock Exchange listed retail group. The umbrella Supply Agreement, ("contract") with the various appendices detailing each pharmaceutical product to be supplied is expected to be fully executed before the end of September, 2011. Because of the time required to have each of Moxisign's drug dossiers registered with South Africa's Medicine Control Council ("MCC") before supply can begin, the contract is expected to run from January 2013 for a renewable five year term, and will cover various generic pharmaceutical products. As such, and subject to the final Supply Agreement being executed by all relevant parties, revenues from this contract will only be generated once MCC approves each drug dossier. The contract provides for additional generic drugs to be added by Moxisign for the duration of the contract term.

Dr. Lisa Ramakrishnan, President and CEO of Vantage Health, noted: "It has always been our intention to have our Moxisign subsidiary focused on the South African private sector as an adjunct to its public sector efforts. In terms of volume potential, we had, as one of our main priorities, the goal of partnering with an established and significant South African retail entity."

About Vantage Health

Vantage Health is an African based health care products and medical consumables supply company focused on building its core supply business through government and local partnerships, and alleviating the burden of HIV/AIDS and disease on the African continent. The company currently has two subsidiaries, Moxisign (PTY) Ltd., a South African entity 49% owned by Kopano Ke Matla Investment Company, the investment arm of the Congress of South African Trade Unions ("COSATU"), and Vantage Health Tanzania Limited, 49% owned by Tanzanian investors. Vantage Health intends to create a healthcare company with a dominant presence in sub Saharan Africa in the pharmaceutical/medical supply and manufacturing sectors, as well as the construction of hospitals, maternal obstetric units, and clinics.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or if they prove incorrect, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the Company's reports filed with the Securities and Exchange Commission. The Company assumes no obligations and does not intend to update these forward-looking statements.

Vantage Health is a US company (OTC:BB – ticker symbol VNTH) recently incorporated and public since February 2011 with the goal of providing healthcare related products and services in sub Saharan Africa.

For more information about Vantage Health, please contact:
Dr. Lisa Ramakrishnan / Karen Sylvester
Tel:  +27 (0) 21 813 6863
Fax:  +27 (0) 86 604 7593
ceo@vantagehealth.co.za
www.vantagehealthgroup.com


'/>"/>
SOURCE Vantage Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
6. St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors
7. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
8. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
9. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
10. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
11. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business ... focus on current legislative activity and the latest regulatory concerns impacting RBMA members. ... Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons ...
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... ... ... On May 24, the Congressional Budget Office (CBO) projected that the amended ... would result in 23 million Americans losing their health insurance by 2026 as compared ... Affordable Care Act (ACA). , “It is clear from the CBO analysis that ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a new assisted ... more than four acres of land at 5620 Sohl Avenue in Hammond, serves older ... building includes 125 studio and one-bedroom apartments. Each of the private apartments at Silver ...
Breaking Medicine News(10 mins):